Recce Pharmaceuticals Ltd. announced the Australian Patent Office issued notification of intent to grant Recce patent family three, “Anti-Virus Agent and Method for Treatment of Viral Infection”. The Australian Patent is expected to grant claims relating to RECCE® 327 (R327) and anti-viral formulation RECCE® 529 (R529), most notably: Composition/method of manufacture of RECCE® anti-infectives. Use of R327 or R529 for the treatment of viruses having a lipid envelope or coat, examples being SARS-CoV-2 and coronaviruses, influenza viruses, (human immunodeficiency virus) HIV, hepatitis, Ross River and herpes viruses.

Administration of R327 or R529 by oral, injection, inhalation and transdermal dose applications.